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Background: Hard consistency, developed under the influence of tumor cell factors, is a characteristic feature of a
breast tumor. Activation of resident fibroblasts leading to a myofibroblast phenotype is the principal feature that
orchestrates this fibrotic process. The aim of this study was to assess the effects induced by TGF-β1, a growth factor
abundantly present in tumor microenvironment, on the molecular mechanisms that mediate myofibroblastic
differentiation of normal human mammary fibroblasts.
Methods: We used an immortalized fibroblastic cell line derived from normal mammary tissue (RMF-EG cells) to
study the effect of TGF-β1 in the expression of α-SMA and CTGF as markers of myofibroblastic differentiation. The
influence of redox status and JNK activity on TGF-β1-induced transcriptional activity was measured by a luciferase
reporter assay. We also used a shRNA approach to evaluate the influence of NOX4 in myofibroblastic differentiation.
Results: TGF-β1 stimulates the expression of myofibroblast markers α-SMA and CTGF. Using a NOX inhibitor (DPI)
and cells expressing a shRNA for NOX4, we demonstrated that TGF-β1 promotes an oxidative environment that
favors myofibroblastic differentiation. We also found that activation of c-Jun N-terminal kinase is required for
TGF-β1-dependent expression of CTGF, NOX4 and α-SMA.
Conclusions: Human mammary stromal fibrosis, evaluated by the expression of early and late markers as CTGF and
α-SMA, depends on the activation of JNK signaling pathway. Our results show that JNK activation is an early event
that precedes the increase in ROS levels leading to myofibroblastic differentiation and tumor fibrosis, suggesting
that inhibition of JNK may be used a method to interrupt the development of tumor desmoplasia.
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Interactions between stromal fibroblasts and migratory
cells at the primary site of tumors create a supportive
microenviroment for cancer growth and survival, evasion
of immune surveillance and metastatic potential [1,2].
Given their abundance in the tumor site and the variety of
functions described in the literature, tumor fibroblasts
have been proposed as key players in the acquisition of
malignant properties by carcinoma cells [3].* Correspondence: jmartine@inta.uchile.cl
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unless otherwise stated.It is currently known that cells of the tumor paren-
chyma and stroma are engaged in an active crosstalk,
and that the composition of the stroma and the nature
of tumor-stromal interactions reciprocally change over
time together with tumor progression [4]. Thus, stromal
soluble factors can modify the invasive potential of car-
cinoma cells, in turn epithelial features are responsible
for the stromal desmoplastic response that characterizes
some types of tumors [5]. On the other hand, it has also
been demonstrated that the normal microenvironment
functions as a non-permissive barrier to block tumor ini-
tiation and/or progression [6]. The protective role of
normal stroma was also confirmed in a model of human
breast morphogenesis in which authors found that thistd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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broblastic stroma [7].
Several studies provide evidence that oxidative stress,
produced by an excessive production of Reactive Oxigen
Species (ROS), constitutes an effective environmental
stimulus for tumor progression [8]. ROS exerts a key role
in a variety of processes associated with epithelial malig-
nancy such as cell proliferation, epithelial-mesenchymal
transition (EMT), angiogenesis, apoptosis evasion and en-
hancement of metastatic potential [9]. Endogenous gener-
ation of ROS arises from two main sources: mitochondria
and the NAD(P)H oxidase (NOX) system [10]. In non-
phagocytic cells, the NOX family is a key component of
the so-called “redox signaling system” which regulates
many cellular responses by modulating the intracellular
ROS content. Previous work of our group showed that an
enhancement of stromal NOX-4 expression and the sub-
sequent increase of intracellular ROS production stimu-
lated by TGF-β1 contained in an epithelial conditioned
medium, constitutes a permissive element in the acquisi-
tion of migratory properties by carcinoma cells [11].
TGF-β1 has been identified as one of the main tumor-
derived soluble factor that alters the stroma toward
cancer progression by promoting the differentiation of
stromal fibroblasts to a myofibroblastic phenotype [12].
The prevalence of myofibroblasts in the cancer micro-
environment has been shown in many different types of
cancer including colon, liver, lung, prostate, ovary, pan-
creas, and breast [13]. This “activated” form of stromal
fibroblasts allows the growth in volume of fibrotic tu-
mors, enhances contractile properties and provokes
changes in the extracellular matrix (ECM) composition
[14]. Contractibility is mainly achieved by the incorpor-
ation of α-smooth muscle actin (α-SMA) into stress fi-
bers, molecules whose expression is controlled by the
joint action of growth factors like TGF-β, specialized
ECM proteins like the fibronectin splice variant ED-A
FN and mechanical forces derived from changes in
ECM composition [15].
Increasing evidence indicates that the rather linear
view through which TGF-β signaling occurs by the sin-
gle activation of Smad pathway, does not account for
the variety of responses obtained under TGF-β stimula-
tion. The emergence of the concept of non-Smad-TGF-β
signaling has provided a more complete understanding
of the wide and diverse spectrum of TGF-β cellular re-
sponses [16]. The molecular mechanisms underlying
the profibrotic effects of TGF-β is a good example of
this dilemma. In spite of several studies conducted in
many different cellular systems, using different experi-
mental approaches, the specific mechanism that accounts
for TGF-β-dependent expression of fibrotic markers, has
not been fully elucidated. Thus, an important area of study
should consider the relative importance of the canonicaland non-canonical pathways in TGF-β-dependent fibro-
genic gene responses [17].
In the present work, using a stromal cell line derived
from normal breast tissue, we show that TGF-β1-
dependent expression of fibrotic markers, such as α-
SMA and connective tissue growth factor (CTGF),
depended on the establishment of a redox threshold
reached by the early expression of NOX-4. Moreover, we
also demonstrate that c-jun N-terminal kinase (JNK)
activation constituted a key step for the expression of
both NOX-4 and fibrotic markers putting the TGF-β-
dependent activation of this route as an initial event
during the breast stromal myofibroblasts differentiation
process.
Methods
Cell culture, cell line and chemicals
Human cell line RMF-EG [7] was a generous gift from Dr.
Charlotte Kupperwasser (Tufts University, MA). These cells
were cultured in DMEM/F12 (Invitrogen Carlsbad, CA),
supplemented with 10% fetal bovine serum (FBS) (Hyclone,
Logan UT) and maintained in a humidified atmosphere of
37°C, 5% CO2. Human Recombinant TGF-β1 was pur-
chased from R&D Systems (Minneapolis, MN). SP600125
and SIS3 were purchased from Merck (Darmstadt, HD,
DE). Diphenyleniodonium chloride (DPI) and 2′,7′-dichlor-
odihydrofluorescein diacetate (H2DCFDA) were acquired
from Sigma Aldrich (St. Louis MO).
Treatments, western blot and antibodies
RMF-EG cells were seeded in 60 mm dishes and pretreated
1 hour before the onset of TGFβ-1 stimulus with: 2.5 μM
DPI, 10 μM SP600125 or 3 μM SIS3, in order to inhibit
ROS production, JNK or Smad3 activity, respectively.
After the corresponding treatments, cells were resus-
pended in lysis buffer (50 mM HEPES, pH 7.4, 150 mM
NaCl, 2 mM MgCl2, 2 mM EGTA, 1% Triton X-100 and
10% glycerol) supplemented with complete protease in-
hibitors (Roche, Mannheim). Protein concentration was
determined by the Bradford method (Fermentas, Mary-
land). Protein extracts were heat denatured in SDS-
Sample buffer (240 mM Tris–HCl, pH 6.8, 8% SDS, 40%
glycerol and 20% 2-mercaptoethanol). Equal amounts of
protein from different treatments were resolved by SDS-
PAGE in 10% polyacrylamide gels and electrotransferred
to polyvinylidenedifluoride (PVDF) membranes using a
buffer containing 24 mM Tris, 194 mM glycine and 20%
methanol. Proteins were further analyzed using the ECL
chemiluminescence detection kit (Amersham, Arlington
Heights, FL). The immunoreactions were achieved by in-
cubation of the membranes, previously blocked with a
solution containing 5% BSA in Tris-buffered saline (TBS)
and 0.05% Tween 20 (Sigma, St. Louis, MO), with the fol-
lowing antibodies: rabbit anti-phospho (Thr183/Tyr185)
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(Danvers , MA), rabbit anti-JNK1,2 (sc-7345) and goat
anti-CTGF (sc-14940) were from Santa Cruz (Santa
Cruz, CA), rabbit anti-NOX-4 (ab81967), mouse anti-α-
SMA (ab7817) and rabbit anti-Smad3 (phospho S423 +
S425) antibodies (ab52903) were from Abcam (Cambridge,
MA) and mouse anti-Smad3 (MA5-15663) from Pierce
Biotechnology (Rockford IL.). Secondary antibodies against
mouse, rabbit and goat conjugated to peroxidase were
purchased from Rockland Immunochemicals (Gilbertsville,
PA). Densitometric analysis of western blot bands was
performed using Molecular Imaging Software, version
4.0 of Kodak (Rochester, NY).
Reporter assay
Reporter assays using TGF-β-responsive promoter 3TP-
Luc constructs (kindly donated by Dr. E. Brandan, Pontifi-
cia Universidad Católica de Chile) were performed as
described previously [18], in cells under the stimulus of
TGF-β1 in the presence or absence of DPI or SP600125,
as indicated above. All transient transfection experiments
were carried out using TransIT-2020 reagent as vehicle
for plasmids according to manufacturer instructions
(Mirus, Madison, USA). Relative luciferase units were
determined using a Dual Luciferase Reporter Assay System
kit (#E1960 from Promega, Madison WI) in a Berthold
FB12 luminometer. The pRL-tk Renilla luciferase vector
(Promega, Madison WI) served as internal control to
correct for transfection efficiency and normalization.
Measurement of intracellular redox state
The oxidation-sensitive fluorescent probe 2′,7′-dichloro-
dihydrofluorescein diacetate (H2DCFDA) was used to
analyse the total intracellular content of ROS [11]. In a
representative assay, RMF-EG cells were incubated with
5 μM H2DCFDA in serum- and phenol red-free medium
(Gibco Invitrogene, CA) for 30 min at 37°C. Cells were
then washed and lysed with 0.1 N NaOH, and fluores-
cence was monitored using a microplate fluorometer
(Spectra MAX, Gemini EM, Molecular Devices) with
wavelengths of 480 and 530 nm for excitation and emis-
sion, respectively [19]. In experiments in which ROS pro-
duction was exogenously modulated, RMF-EG cells were
pre-treated for different periods of time with 5 ng/ml of
TGF-β1 in presence or absence of 10 μM SP600125 before
fluorometric determination of ROS.
Quantitative PCR
Total RNA was isolated from control and TGF-β1-
stimulated RMF-EG cells, treated or not with 2.5 μM DPI
or 10 μM SP600125, with Trizol (GIBCO) according to
the manufacturer’s instructions. mRNA expression was
assessed by real time PCR using a Light Cycler instrument
(Roche, Germany). The reaction was performed using100 ng of cDNA and LightCycler®FastStart DNA Master
SYBR Green I kit (Roche) in a final volume of 20 μL. All
the reactions were performed in duplicate, and negative
controls were included. The primers used were: NOX4,
forward: 5′TAGATACCCACCCTCCCG3′, reverse: 5′TG
GGCTCTTCCATACAAATC3′, PCR product size: 169pb;
α-SMA, forward: 5′ GCCGACCGAATGCAGAAGGA 3′,
reverse: 5′ TGCGGTGGACAATGGAAGGC3′, PCR prod-
uct size: 190pb; CTGF, forward: 5′TTGGCCCAGACC
CAACTATG3′, reverse: 5′ CAGGAGGCGTTGTCATT
GGT3′, PCR product size: 240pb and GPDH, forward 5′
CAAAATCAAGTGGGGCGATGCTG 3′, reverse 5′ TGT
GGTCATGAGTCCTTCCACGAT 3′. In every case,
mRNA expression was normalized by viable cell number
at the end of the experiment and using GAPDH as loading
control.
Lentivirus production and infection of breast stromal cells
HEK293FT cells were grown in 60 mm culture plates to
80–90% confluence; Lipofectamine 2000 reagent (Invi-
trogen) was used to transfect cells (following the manu-
facturer’s instructions) with the pVSVg, pΔ8.9, and
pLKO.1-shRNA plasmids (TRCN46088 and TRCN46090
to NOX4 and TRCN1056 and TRCN1013 to JNK1 and
2 respectively, Sigma-Aldrich, St Louis MO) at a 1:2:3
ratio, respectively, with a maximum total DNA of 10 μg.
pLKO.1 non-target shRNA (Sigma-Aldrich, St Louis
MO) was used as a control. After 16–18 h, the culture
medium was replaced and cells were maintained at 37°C
for 48 h. Supernatants containing pseudo-typed particles
were collected, filtered through a PVDF filter (0.45 μm
pore size), and concentrated by centrifugation at 3800 ×
g for 30 min at 4°C in an Amicon Ultra-15 centrifugal
filter device (100 K, Merck Millipore) according to the
manufacturer’s instructions. Aliquots of concentrated
viral particles were immediately stored at − 80°C. RMF-
EG cells were plated in 60 mm culture plates and in-
fected for 48 h with 40 μl lentiviral particles containing
shRNA-NOX4 or JNK1,2 or control plasmids. After-
wards, cells were stimulated with 5 ng/ml TGF-β1 for
24 h and lised for western blot analysis.
Immunofluorescence analysis
RMF-EG cells (5x104) were plated on glass coverlips
(24 h) and then incubated for 1 h with 2,5 μM DPI or
10 μM SP600125 previous to a 48 h incubation with 5 ng/
ml of TGF-β1 in serum-free medium. After PBS washing,
cells were fixed with 4% paraformaldehyde in PBS, perme-
abilized with 0.1% Triton X-100 in PBS and processed for
immunofluorescence as previously described [20]. Primary
mouse monoclonal antibody directed to human α-SMA
(ab7817) was from Abcam (Cambridge, MA) and the
fluorescence secondary antibody was form Invitrogen,
Molecular Probes, Carlsbad, CA. Nuclei were stained with
Figure 1 TGF-β1 increased intracellular ROS production and
CTGF, NOX-4 and α-SMA mRNA expression. Time-course
evaluation of CTGF, NOX-4 and α-SMA mRNA expression performed
by qPCR. RMF-EG cells cultures, previously deprived of serum were
stimulated with 5 ng/ml of TGF-β1 and their mRNA levels were
evaluated at the indicated times. In a parallel group of cells, intracellular
ROS production was assessed by measuring fluorescence generated
after H2DCFDA incubation. Figure is representative of three independent
experiments. Values were normalized by number of viable cells at the
end of the experiment.
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mounted on glass slides and images were collected by
immunofluorescence microscopy with a digital camera
(Carl Zeiss, Dresden, Germany).
Knocking down of Smad2/3 pathway by siRNA
To investigate whether TGF-β1-dependent activation of
Smad2/3 pathway plays a role in NOX4 expression, we
evaluated mRNA expression of NOX4 after knocking
down Smad2/3. We used a commercial pool of small
interfering RNAs directed to this molecule (Santa Cruz,
sc-37238 and sc-37007 as a control) and used the
TransIT-siQUEST transfection reagent (Mirus) according
to manufacturer instructions.
Statistical analysis
Experimental data are presented as mean ± standard error
and were performed in triplicate. Data were subjected to a
variance analysis; comparisons among groups was per-
formed by Anova-Tukey using the GraphPad Prism 5 soft-
ware (GraphPad Software, San Diego, CA). A value of
p < 0.05 was considered statistically significant.
Results
TGF-β1-stimulated NOX4 and CTGF expression and
intracellular ROS production preceded α-SMA expression
To analyze whether TGF-β1 exerts its stimulus on the ex-
pression of molecules relevant to myofibroblastic differen-
tiation in a sequential manner, we performed a quantitative
PCR (qPCR) analysis of α-SMA, CTGF and NOX4 mRNA
expression in a time range from 2 to 48 h. During the same
time range we analyzed the intracellular ROS production
using H2DCFDA as a probe. Under a 5 ng/ml TGF-β1
stimulus, CTGF reached an early expression maximum
around 4 h that was maintained throughout the time
period (Figure 1). NOX4 expression increased in a linear
manner reaching its expression peak around 16 h. On the
other hand, α-SMA displayed a later expression, reaching
its peak around 24 h. Intracellular ROS production in-
creased in expression from 4 to 16 hours, at which time its
maximum level was reached (Figure 1).
Expression of myofibroblast markers stimulated by
TGF-β1 was attenuated by NOX inhibiton
In non-phagocytic cells, the NOX family of enzymes
constitutes a key element providing the so-called
“redox signaling system” which regulates many cellular
functions [21]. To test whether intracellular redox level
controlled by NOX was able to modify the TGF-
β1-dependent expression of canonical myofibroblast
markers in breast stromal cells, we subjected RMF-EG
cells to a 1 hour pretreatment with 2.5 μM of the flavopro-
tein inhibitor diphenyleniodonium chloride (DPI), pre-
vious to TGF-β1 stimuli. The time-course mRNAexpression of α-SMA and CTGF in the presence or
absence of DPI displayed inhibition at all time points
(Figure 2A). When the same phenomenon was analyzed
in terms of protein expression, (Figure 2B) a very similar
picture arose, revealing a significant inhibition of the ex-
pression of both markers in the presence of DPI. After
correction for cell viability, differences between control
and DPI-treated cells remained significant (Figure 2C). To
analyze whether this inhibition was the result of a block-
ade of the TGF-β1 transcriptional activity, we performed a
3TP-luc reporter assay to measure the effect of DPI in
ALK5-Smad2/3 pathway activation. Preincubation of RMF-
EG cells with DPI generates a dose-dependent inhibition of
reporter activity (Figure 2D).NOX4 knockdown blocked TGF-β1 stimulus on α-SMA
expression
Using RMF-EG cells we have previously demonstrated
that production of ROS in response to TGF-β1 was
mainly accomplished by a previous increase on NOX-4
expression [11]. To test whether the ROS-dependent
stimulus on α-SMA protein expression was attributable
to a TGF-β1 stimulus on NOX4 expression/activity, we
used a lentiviral based shRNA strategy to knock down
NOX4. In doing so, we infected for 48 h RMF-EG cells
with viral particles (prepared as described in Material
and Methods) carrying a sequence specific shRNA tar-
geting NOX4. As Figure 3 shows, RMF-EG lentivirus in-
fected cells expressed a diminished level of NOX-4,
Figure 2 NADPH oxidase activity modulated the expression of CTGF and α-SMA. A. Inhibition of NOX activity decrease CTGF and α-SMA
expression. Time-course expression of CTGF and α-SMA mRNA evaluated by qPCR in 5 ng/ml TGF-β1- stimulated RMF-EG cells pre-treated or not with
DPI. B. DPI inhibited TGF-β1-induced CTGF and α-SMA protein expression. RMF-EG cells were treated with TGF-β1 (5 ng/ml) in the presence or absence
of 2,5 μM DPI. Protein expression of CTGF and α-SMA was evaluated by western blot after 24 h and 72 h, respectively. C. Densitometric analysis of
western blots bands in B. Columns represent the mean of α-SMA to Tubulin signal and CTGF to Actin signal from three independent experiments; bars
± SE D. DPI inhibits TGF-β1-induced 3TP-luc luciferase reporter activity. RMF-EG cells transiently transfected with 3TP-luc luciferase construct and were
pre-treated or not with DPI before stimulation with TGF-β1 for 16 h. Values are average of three separate experiments performed in triplicate.
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protein expression.
TGF-β1 stimulated JNK activation, independent of Smad3
It has been demonstrated that intracellular TGF-β1 signal-
ing occurs by the activation of an array of signaling routes.
Among them, Smads and c-Jun N-terminal kinase (JNK)
seem to be the most prominent and probably exhibit some
level of interaction between each other [22]. To evaluate
the activation of the JNK pathway by TGF-β1 we exam-
ined the phosphorylation pattern of JNK in a time-course
assay. Figure 4A shows that TGF-β1 induced an early acti-
vation of the route with a peak around 10 min and aFigure 3 NOX-4 knockdown reduced α-SMA expression in response t
(prepared as described in Material and Methods) carrying a sequence specific
period of 48 h, in the presence or absence of 5 ng/ml of TGF-β1 proteins wer
mean ± SE of α-SMA signal to Actin from densitometric analysis of three indereturn to the basal state through the remaining time of
stimulus. To investigate whether a previous activation of
Smad3 was required for JNK activation, cells were pre-
treated with SIS3, a specific inhibitor of Smad3, prior to
TGF-β stimulus. As Figure 4B shows, JNK phosphoryl-
ation was not affected, neither at 10 nor 60 minutes, sug-
gesting that JNK activation was, in fact, independent of
previous Smad3 activation regardless of time.
JNK inhibition prevented the expression of
myofibroblastic markers
To evaluate whether the TGF-β1-stimulated JNK activa-
tion had a functional consequence in the expression ofo TGF-β stimulus. A. RMF-EG cells were infected with viral particles
shRNA targeting NOX4 or a non-related sequence. After an infection
e analyzed by western blot to a-SMA and NOX4. B. Columns represents
pendent experiments.
Figure 4 TGF-β-dependent activation of c-JNK was independent
of Smad3 activation. A. Serum-deprived RMF-EG cells were incubated
with 5 ng/ml of TGF-β from 10 to 90 min. The levels of phosphorylated
and total JNK were evaluated by western blot. B. RMF-EG cells were
pre-treated with 3 μM SIS3, specific inhibitor of Smad3, and stimulated
with 5 ng/ml TGF-β as in B. c-JNK and Smad3 activation were evaluated
by western blot.
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with SP600125, specific inhibitor of JNK, prior to TGF-β1
stimulus. As Figure 5A, B and C show, both α-SMA and
CTGF mRNA and protein expression were inhibited in the
presence of the JNK inhibitor. To test whether the
SP600125 inhibition of α-SMA and CTGF expression
operates via the reduction of TGF-β1 transcriptional activ-
ity, we used the 3TP-luc reporter assay to measure the
effect of SP600125 in the ALK5-Smad2/3 pathway activa-
tion. As Figure 5D shows, incubation of RMF-EG cells with
SP600125 prior to TGF-β1 stimulus, generated a reporter
activity inhibition. Considering that c-Jun expression is also
under the control of JNK [23], our data may suggest that
SP600125 exerts its action by blocking the activation of the
AP-1 site of 3TP-luc reporter. To confirm that SP600125
was able to inhibit α-SMA expression, we performed an
immunofluorescence analysis in RMF-EG cells treated with
TGF-β1. Figure 5E shows that in the presence of the in-
hibitor there was a negligible expression of α-SMA in cells
treated with TGF-β1. A similar result was obtained when
cells were pre-treated with 2.5 μM DPI reinforcing the
suggestion that a NOX activity is involved in α-SMA
expression as shown in Figure 2.
JNK activity controlled intracellular redox status through
modulation of NOX4 expression
To test whether the JNK activation played a significant
role on the acquisition of the intracellular redox level
needed for myofibroblast markers expression, we usedtwo different experimental approaches. First, we analyzed
the effect of JNK inhibitor on both, NOX4 protein expres-
sion and intracellular ROS production. Figure 6A and B
show that pre-incubation of RMF-EG cells with 10 μM
SP600125 produced a reduced NOX-4 protein expression
that correlated with mRNA expression in a time-course ex-
periment (Figure 6C). In the same time-course approach,
pre- treatment of RMF-EG with SP600125 provoked a de-
creased production of H2DCFDA-reactive intracellular
ROS, (Figure 6C) which becomes evident after 24 h of
TGF-β1 stimulus, period in which NOX-4 expression
reached its maximum level as is shown in Figure 1.
Secondly, we knocked down the expression of JNK using a
lentiviral strategy using a shRNA directed to JNK1 and 2.
Figure 6D shows that RMF-EG cells expressing the shRNA
did not respond to TGF-β stimulus, displaying a decreased
expression of α-SMA and NOX4. To test whether Smad2/
3, the canonical TGF-β signaling transducer, participated
in NOX4 expression, we performed a knocking down of
Smad2/3 using a siRNA approach. As Figure 6F shows,
under this experimental condition, the expression of
NOX4 was not affected, reinforcing our interpretation of
the role of JNK in NOX4 expression.
Discussion
Breast tumours belong to a group of neoplastic lesions
which, under the influence of carcinoma cell products,
originate a fibrous structure responsible for the hard
consistency of the tumoral mass [24]. This fibrotic re-
sponse is largely due to the activity of TGF-β, a growth
factor that directly induces the transdifferentiation of
fibroblasts into myofibroblasts [12]. Results from this work
support the hypothesis that TGF-β1 plays a critical role in
the development of breast fibrosis. Our findings indicate
that this activity depends first on the activation of c-Jun
terminal kinase and the subsequent NOX4-dependent
ROS production.
Using an immortalized cell line derived from normal
breast tissue, we demonstrated that TGF-β1 induces a se-
quential expression of CTGF, NOX-4, and α-SMA. These
consecutive events also involve an increase in TGF-β1-
dependent ROS production. The inhibition of ROS pro-
duction by DPI suggests that at least a fraction of this
redox level depends on a NAD(P)H oxidase activity, the
target of the inhibitor. The blocking of NOX activity pro-
duced an inhibition of the expression of myofibrotic
markers (shown in Figure 2), where CTGF and α-SMA ex-
pression were strongly inhibited by DPI at mRNA and
protein levels after 24 h of TGF-β1 stimulus. Previous
work, also performed in fibroblastic cells, has suggested
that NOX-4 is the isoform responsible for the generation
of the redox environment that, in turn, favours myofibro-
blastic differentiation [25,26]. Prior work of our research
group found that NOX-4 is the only isoform of NOX
Figure 5 Inhibition of c-JNK activity reduced α-SMA/CTGF expression and partially reduced TGF-β-dependent transcriptional activity.
A. CTGF and α-SMA mRNA time-course expression in RMF-EG cells. Serum-deprived RMF-EG cells were pre-treated or not with 10 μM SP600125 for
16 h and further stimulated with 5 ng/ml of TGF-β1 at the indicated times. mRNA expression of both genes were evaluated by qPCR. B. RMF-EG cells
were treated with TGF-β1 (5 ng/ml) in the presence or absence of 10 μM SP600125. Protein expression of CTGF and α-SMA was evaluated by western
blot after 24 h and 72 h respectively. C. Densitometric analysis of western blot bands in B. Columns represents mean ± SE ratio of α-SMA to Tubulin
and CTGF to Actin signal from three independent experiments. D. RMF-EG cells were transiently transfected with 3TP-luc luciferase construct and then
pre-treated or not with SP600125 before stimulation with TGF-β1. Values presented are representative of three separate experiments performed in trip-
licate. E. Immunofluorescence analysis to α-SMA of control and TGF-β1-treated (48 h) RMF-EG cells preincubated in the presence or absence of DPI
(2,5 μM) or SP600125 (10 μM). Figure is a representative image of an experiment performed in duplicate.
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control [11]. In this stromal cellular system, NOX-4 was in
fact involved in the expression of fibrotic markers. Consid-
ering that TGF-β-dependent NOX-4 expression is an early
event in the TGF-β-dependent myofibroblastic differenti-
ation, it is possible that the establishment of a redox
threshold is a prerequisite for the long-term myofibroblas-
tic process. It has been previously demonstrated that TGF-
β1 was able to induce mitochondrial ROS production at
early times and stimulated CTGF gene transcription at
24 h [27]. Our results showing that DPI was able to blockCTGF mRNA expression as early as 4 h post stimulus can
be explained because DPI is a fairly unspecific drug that
inhibits both NOX4 and mitochondrial ROS production
[28]. Therefore, it is possible that, at early time points,
CTGF gene expression was stimulated by a slight increase
in TGF-β1-induced mitochondrial ROS and later, ROS
production and CTGF expression was sustained by NOX4
activity.
Searching for a molecular target of the TGF-β→NOX-
4→ROS signaling axis, the nuclear MAPK phosphatase-
1 (MKP-1) has been proposed as a direct oxidizable
Figure 6 NOX-4 expression and intracellular ROS production depended on c-JNK activity. A. Serum-starved RMF-EG cells were pretreated
or not with 10 μM SP600125 for 16 h and stimulated for 24 h with 5 ng/ml of TGF-β1. NOX-4 protein expression was evaluated by western
blot. B. Densitometric analysis of western blot bands in A. Columns represents mean ± SE ratio of NOX-4 to Actin signal of three independent
experiments. C. Time-course of NOX-4 mRNA expression in TGF-β1-stimulated RMF-EG treated or not with SP600125 measured by qPCR. D.
Time-course of intracellular ROS production evaluated by fluorescence generated with H2DCFDA incubation in TGF-β1-stimulated RMF-EG cells
pre-treated or not with 10 μM SP600125. Values are representative of three separate experiments. E. RMF-EG cells were infected either with
viral particles carrying a sequence specific shRNA targeting JNK1,2 (shJNK1,2) or a non-related sequence (shCTL) and treated or not with 5 ng/
ml of TGF-β. α-SMA, NOX4 and JNK protein expression was evaluated by western blot. Figure is a representative result of an experiment
performed in duplicate. F. Smad2/3 knocking down does not affect NOX4 expression. RMF-EG cells (3x105) transfected with a siRNA directed
to Smad2/3 were stimulated with 2.5 ng/ml of TGF-β1 for 24 h and mRNA expression was analyzed by qPCR.
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in an induction of JNK/p38 phosphorylation and PAI-1
expression [29]. In agreement with these results we found
that activation of 3TP-luc, reporter construct that displays
a ~400-nucleotide region of the PAI-1 promoter, is alsosensitive to ROS, given that its activity decays in the pres-
ence of DPI in a dose-dependent manner (Figure 2).
In spite of the fact that many of the transcriptional
responses to TGF-β are mediated by the activation of
Smad proteins, it has been demonstrated that these
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between Smad signaling and other signaling systems [30].
Thus, during the last decade, growing evidence has sup-
ported the idea that non-Smads pathways actively partici-
pate in TGF-β signaling [31]. Some of the main alternative
pathways activated by TGF-β in the context of cancer pro-
gression are the p38 and c-Jun N-terminal kinase (JNK),
pathways belonging to the MAPK family [25]. Using a
specific inhibitor of JNK, our results show that the TGF-
β-dependent stimulus on fibrotic markers in RMF-EG
cells (at mRNA and protein levels) depended on the
factor-dependent activation of JNK. Our results suggest
that inhibition of JNK by SP600125 blocked TGF-β-
dependent early CTGF expression in a ROS-independent
manner. However, after 16 h, JNK inhibition diminished
ROS production simultaneously to inhibit NOX4 expres-
sion (Figure 6D and C) suggesting that, at this time,
NOX4 activity sustains ROS production in a JNK-
dependent manner.
It has long been recognized that intracellular production
of ROS activates JNK and, in many cases, a specific require-
ment of NOX activity has been demonstrated [32]. For ex-
ample, using prostatic fibroblasts, Sampson et al. have
proposed that TGF-β-dependent JNK activation requires a
prior stimulus on NOX-4, putting the NOX-4 expression
(and the subsequent ROS production) as the initial step in
a cascade of events that ends in myofibroblastic differenti-
ation. Our results, from breast stromal cells, offer an alter-
native understanding. Results in Figure 6 show that NOX4
protein expression and ROS production are clearly affected
by both pharmacological inhibition and knocking down of
JNK, putting this signaling pathway, and not the canonical
Smad2/3 route (Figure 6F), as the initial signal of a sequen-
tial mechanism that ends in tumor fibrosis. In addition,
other studies have proposed that JNK is involved in fibrotic
response. In fact, it has been described that, under the ef-
fect of TGF-β, CTGF expression and corneal wound heal-
ing in vivo are mediated by JNK activation [33]. Moreover,
CC-930, a selective inhibitor of JNK, which is in a clinical
trial as an antifibrotic drug (www.clinicaltrials.gov; trial
identifier NCT01203943), has been shown to exert a potent
antifibrotic effect, preventing myofibrolasts differentiation
and the accumulation of collagen in both in vitro and
in vivo models of systemic sclerosis [34].
In conclusion, our results suggest that JNK activation
is an early and critical step in the TGF-β1-dependent
myofibroblastic differentiation process in normal human
breast fibroblasts. Stimulation of JNK causes a sequential
transcriptional activation that promotes an early ROS-
independent stimulation of fibrotic markers such as
CTGF (Figure 5A and Figure 6D) and, at later time
points, the establishment of a NOX-4-dependent long-
term α-SMA expression, which generates a pro-fibrotic
microenvironment that promotes cancer progression.Conclusion
These results provide experimental evidence supporting
the hypothesis that TGF-β1-induced JNK activation pre-
cedes the factor-dependent increase in intracellular ROS
production, leading to myofibroblastic differentiation
and tumor fibrosis. We found that the activity and ex-
pression of JNK are uniquely involved in the expression
of NOX4 and in early (e.g. CTGF) and late (e.g. α-SMA)
fibrotic markers.
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